Hannu Kankaanranta MD, PhD, Professor, FERS Krefting Research Centre, Gothenburg University, Sweden

Faculty of Medicine and Health Technology, University of Tampere, Finland Department of Respiratory Medicine, Seinäjoki Central Hospital, Finland Specialist in Respiratory Medicine and Allergology Specialist in Clinical Pharmacology and Drug Therapy Associate professor (docent) of pharmacology



Berlin DA, et al. NEJM 383:2451-2460, 2020

- COVID-19 infection is associated with cardiac, respiratory and neurological long-term consequences
- Most studies follow hospitalized patients <u>Unknown:</u>

Consequences of COVID-19 at population level?

Severity of COVID-19 infection associated with long-term consequences in population?

Effect of COVID-19 in respiratory cohorts?

Risk factors of COVID-19 infection, its severity and long-term consequences at population level?

Multi-organ long-term COVID-19 outcomes at population level?









Nwaru BI, et al. BMJ Open 9:e027808, 2019

Objectives of the study

By collecting new clinical and lab data to be added to already collected extensive historical questionnaire and clinical data, we will investigate the:

- 1. Long-term prognosis of COVID-19 disease with focus on cardio-respiratory and neurolopsychological morbidity and mortality
- 2. Phenotypic features or clusters of underlying co-morbid conditions related to COVID-19 disease severity
- 3. Differences in long-term prognosis (cardio-respiratory-neuropsychological morbidity and mortality) between phenotypic clusters of COVID-19 severity spectrums
- 4. Effects of COVID-19 infection in patients with asthma and/or COPD
- 5. Multi-organ (lung, heart, neurological) consequences of COVID-19 infection
- 6. Physiological, biochemical and immunological features related to severity and susceptibility to COVID-19 disease



COVID-19 in West Sweden: Longitudinal clinical and registry follow-up of COVID-19 survivors for cardiac, respiratory and neurological outcomes



COVID-19 in West Sweden: Longitudinal clinical and registry follow-up of COVID-19 survivors for cardiac, respiratory and neurological outcomes



Setting

1:2 case-control setting Controls matched for gender, age and place of residence

Aim: To have data from clinical visit with: 360 COVID-patients 720 non-COVID controls

Reasonable number of patients for evaluation: 180 COVID-patients 360 non-COVID controls

<u>General:</u> Informed consent Safety procedures COVID-19 antigen COVID Qs (2 pages)

Laboratory: SaO₂ Full blood count GHbA1c Kreatinin (GFR) N-terminal pro-BNP, Troponin I (TnI) ESR, hsCRP ALAT, ASAT, GGT, AFOS Serum and plasma to freezer

Respiratory questionnairesGener& measurements:& queACTWeighCATWaistVVSAS clin interviewAuditVSAS clin questionnaireSF-8 (0SpirometrySF-8 (0DLCOFeNOSaO2NeuropsychologicalTrail-making testRey Auditory verbalStroop Color-Word THAD

<u>General measurements</u> <u>& questionnaires</u> Weight & height Waist & neck circumference Audit (alcohol) SF-8 (QoL)

<u>Cardio-metabolic</u> <u>& questionnaires</u> NYHA KCCQ MLHFQ Pulse & blood pressure 12-channel ECG Holter ECG (single channel) Bioimpedance

Trail-making test Rey Auditory verbal Learning test (RAVLT) Stroop Color-Word Test (VST) HAD Mental Fatigue Scale (MFS) Sahlgrenska Academy Self-reported Cognitive Impairment Q (SASCI-Q) West Sweden Taste and Smell Questionnaire







SCIFI-PEARL

Register linkage analysis

- Hospitalizations (respiratory reasons, cardiovascular reasons, all reasons)
- Emergency visits (respiratory reasons, cardiovascular reasons, all reasons)
- Medicine use (respiratory, cardiovascular, diabetes)
- Mortality (respiratory, cardiovascular, allcause mortality)
- Absence of work (sick-leaves, pensions; respiratory & CV reasons, all-cause)
- COVID-19-related costs (direct health-care costs and indirect costs)
- Socioeconomic outcomes (employment, income, taxes, social benefits)

Where we are? -1

- Decision to make COVID-study in 2020 by KRC steering meeting
 - Co-PIs: Hannu Kankaanranta and Bright I Nwaru
- Research plan ready & ethical application submitted 5-6/2021
 - Ethical acceptance 27-07-2021
- Applications to SmiNet and VEGA 8-9/2021
 - Positive decisions and data on COVID-infected obtained 9-10/2021
- Ethical amendment application (patient number and neuropsychology) 11-12/2021
 - Accepted 2021-12-23

Where are we now? -2

- New application to VEGA 1-2/2022 to get full COVID-19 related background data
 - Acceptance 09.05.2022
- 2nd amendment done to ethical committee 3-4/2022
 - Some COVID-related Qs
 - Changes in cardiology evaluation
 - Some changes to WSAS questionnaire
 - Accepted April 5, 2022
- First abstracts sent to ERS 2022 congress
- Next: Protocol paper & registration to ClinicalTrials register

First scientific abstracts have been sent to European Respiratory Society Congress 2022

- Does the accuracy of clinician diagnosis of COVID-19 compared to RT-PCR in adults depend on the number and severity of comorbidities?
- Pre-COVID-19 obesity-related asthma phenotypes and risk of COVID-19 infection
- Pre-COVID-19 asthma phenotypes and risk of COVID-19 diagnosis
- Pre-COVID-19 lung function in a general adult population between COVID and non-COVID-19 cases

First patient in May 9, 2022

Respir staff/KRC: Hannu Kankaanranta Daniil Lisik Rani Basna Jan Lötvall Bo Lundbäck Linda Ekerljung Helen Friberg Louise Olaufsson Lina Rönnebjerg Helén Törnqvist Göran Wennergren Lowie Vanfleteren Madeleine Rådinger Bright I Nwaru <u>SCIFI-PEARL:</u> Fredrik Nyberg

unafonden

<u>Neuropsychology/</u> <u>Neuroscience:</u> Fredrik Öhman Michael Schöll <u>Cardiology /clin physiology</u> Niklas Berg Kristjan Karason Antti Tikkakoski

